{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T00:51:23Z","timestamp":1721523083217},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T00:00:00Z","timestamp":1438646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Squamous cell carcinoma of the thymus is a rare thymic epithelial neoplasm that tends to widely metastasize at initial presentation. Because of its rarity, the optimal chemotherapeutic regimen remains uncertain. A gemcitabine and cisplatin regimen has shown promising efficacy in the treatment of other squamous cell carcinomas. We assessed the efficacy and toxicity of this regimen in patients with advanced thymic squamous cell carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Between <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>anuary 2003 and <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>ecember 2012, 13 patients with untreated or unresectable recurrent thymic squamous cell carcinomas, who were treated with gemcitabine and cisplatin, were retrospectively analyzed. The endpoints in this study were clinical response rate, disease control rate, progression\u2010free survival, and overall survival. Significant hematological and non\u2010hematological toxicities were also assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three patients were in <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>asaoka stage <jats:styled-content style=\"fixed-case\">IVa<\/jats:styled-content> and 10 were in stage <jats:styled-content style=\"fixed-case\">IVb<\/jats:styled-content>. The median number of treatment cycles for the present chemotherapy regimen was four. The clinical response and disease control rates were 61.5% and 92.3%, respectively. The median progression\u2010free and median overall survival rates were 14.5 months (95% confidence interval, 9.2\u201319.8 months) and 50.7 months (95% confidence interval, 24.9\u201376.5 months), respectively. Grade 3\/4 hematological toxicities were observed in seven (53.8%) patients, and non\u2010hematological toxicities were mild.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This retrospective analysis demonstrated that gemcitabine plus cisplatin was active against advanced thymic squamous cell carcinoma with manageable toxicity. Gemcitabine may be a novel and alternative agent for advanced thymic squamous cell carcinoma.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.12300","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T07:49:47Z","timestamp":1438674587000},"page":"167-172","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chemotherapy with gemcitabine plus cisplatin in patients with advanced thymic squamous cell carcinoma: Evaluation of efficacy and toxicity"],"prefix":"10.1111","volume":"7","author":[{"given":"Yang","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Peking Union Medical College &amp; Chinese Academy of Medical Sciences  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun\u2010ling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Peking Union Medical College &amp; Chinese Academy of Medical Sciences  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology Cancer Institute\/Hospital Peking Union Medical College &amp; Chinese Academy of Medical Sciences  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Peking Union Medical College &amp; Chinese Academy of Medical Sciences  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,8,4]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"145","volume-title":"Pathology and Genetics: Tumours of the Lung, Thymus and Heart","author":"Marx A","year":"2004"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(03)00555-1"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2009.02.019"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10588"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyd108"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200206000-00012"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31822e71c0"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2013.14.9.5385"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0269-x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0375"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2013.04.078"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(98)70273-9"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(01)03607-4"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11606"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.05.016"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2009.03.031"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9607"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.05.013"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyr089"},{"key":"e_1_2_7_24_1","first-page":"3005","article-title":"Second\u2010line chemotherapy of platinum compound plus CPT\u201011 following ADOC chemotherapy in advanced thymic carcinoma: Analysis of seven cases","volume":"27","author":"Kanda S","year":"2007","journal-title":"Anticancer Res"},{"key":"e_1_2_7_25_1","first-page":"1808","article-title":"Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma","volume":"6","author":"Song Z","year":"2014","journal-title":"J Thorac Dis"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2014.10.006"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1759-7714.12300","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.12300","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.12300","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.12300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T11:14:31Z","timestamp":1695986071000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.12300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/1759-7714.12300"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.12300","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,4]]},"assertion":[{"value":"2015-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-08-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}